{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:15:14Z","timestamp":1788531314887,"version":"build-2803163510"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Radiotheranostic agents enable paired diagnostic imaging and targeted radiopharmaceutical therapy through the selection of appropriate radioisotopes. Radiotheranostics are typically composed of a targeting vector, a chelator or prosthetic group for radiolabeling and an optional linker for optimizing their pharmacokinetic properties. The chemokine receptor 4 (CXCR4) is a promising target for molecular imaging and therapy across a broad range of pathological conditions, including cancer, cardiovascular disorders, infectious and autoimmune diseases. The elucidation of CXCR4 crystal structures, together with extensive structure-activity relationship studies, has accelerated the design of novel small molecule and peptide-based CXCR4-targeted radiopharmaceuticals. These molecules have served as scaffolds that can be chemically modified to optimize their pharmacokinetic properties and maximize accumulation at the target organ. In oncology, the peptide-based theranostic pair Pentixafor\/Pentixather has advanced into early-stage clinical evaluations for imaging and therapy. This review summarizes the current landscape of CXCR4 radiopharmaceuticals, and highlights key structural features and chemical modifications that lead to enhanced receptor affinity as well as improved pharmacokinetic and\n                    <jats:italic>in vivo<\/jats:italic>\n                    targeting properties for theranostic applications.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1923347","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:23:34Z","timestamp":1788528214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimization of next-generation CXCR4 ligands for radiotheranostic applications"],"prefix":"10.3389","volume":"17","author":[{"given":"Itzel Rene\u00e9","family":"Astiazar\u00e1n-Rasc\u00f3n","sequence":"first","affiliation":[{"name":"Department of Basic and Translational Research, BC Cancer Research Institute","place":["Vancouver, BC, Canada"]},{"name":"Department of Radiology, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Basic and Translational Research, BC Cancer Research Institute","place":["Vancouver, BC, Canada"]},{"name":"Department of Radiology, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[{"name":"Department of Basic and Translational Research, BC Cancer Research Institute","place":["Vancouver, BC, Canada"]},{"name":"Department of Radiology, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nucmedbio.2018.01.004","article-title":"[18F]RPS-544: a PET tracer for imaging the chemokine receptor CXCR4","volume":"60","author":"Amor-Coarasa","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/molecules24081612","article-title":"[18F]Fluoroethyltriazolyl monocyclam derivatives as imaging probes for the chemokine receptor CXCR4","volume":"24","author":"Amor-Coarasa","year":"2019","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/2767-9764.CRC-22-0090","article-title":"Mavorixafor, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and inflammatory status of tumor microenvironment in patients with melanoma","volume":"2","author":"Andtbacka","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/blood-2004-06-2289","article-title":"WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12","volume":"105","author":"Balabanian","year":"2005","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","article-title":"The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes","volume":"94","author":"Bleul","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/RLU.0000000000001435","article-title":"Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients","volume":"42","author":"Bluemel","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cncr.33338","article-title":"BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed\/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7150\/thno.101215","article-title":"CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Braitsch","year":"2025","journal-title":"Theranostics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1021\/acs.molpharmaceut.9b00069","article-title":"Development and evaluation of an 18F-radiolabeled monocyclam derivative for imaging CXCR4 expression","volume":"16","author":"Brickute","year":"2019","journal-title":"Mol. Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1021\/jm901530b","article-title":"Synthesis and structure\u2212activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication","volume":"53","author":"Bridger","year":"2010","journal-title":"J. Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e21260","DOI":"10.1096\/fj.202001273R","article-title":"Polyfunctionality of the CXCR4\/CXCL12 axis in health and disease: implications for therapeutic interventions in cancer and immune-mediated diseases","volume":"35","author":"Britton","year":"2021","journal-title":"FASEB J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"263693","DOI":"10.2967\/jnumed.121.263693","article-title":"Imaging of C-X-C Motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-PentixaFor PET","volume":"121","author":"Buck","year":"2022","journal-title":"J. Nucl. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2967\/jnumed.122.264207","article-title":"C-X-C motif chemokine receptor 4\u2013targeted radioligand therapy in patients with advanced T-cell lymphoma","volume":"64","author":"Buck","year":"2023","journal-title":"J. Nucl. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","article-title":"Regulation of CXCR4 signaling","volume":"1768","author":"Busillo","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.7150\/thno.99025","article-title":"PET imaging of CXCR4 expression using [18F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors","volume":"14","author":"Cheng","year":"2024","journal-title":"Theranostics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1667\/RADE-24-00232.1","article-title":"Targeting CXCR4 with 212Pb\/203Pb-pentixather significantly increases overall survival in small cell lung cancer","volume":"204","author":"Christensen","year":"2025","journal-title":"Rare"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41598-019-38745-x","article-title":"Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates","volume":"9","author":"Costa","year":"2019","journal-title":"Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1093\/emboj\/16.23.6996","article-title":"Solution structure and basis for functional activity of stromal cell\u2010derived factor\u20101; dissociation of CXCR4 activation from binding and inhibition of HIV\u20101","volume":"16","author":"Crump","year":"1997","journal-title":"EMBO J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2967\/jnumed.110.085613","article-title":"Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465","volume":"52","author":"De Silva","year":"2011","journal-title":"J. Nucl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.1021\/jm2009716","article-title":"Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4","volume":"54","author":"Demmer","year":"","journal-title":"J. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand","volume":"6","author":"Demmer","year":"","journal-title":"ChemMedChem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8369","DOI":"10.1021\/acs.jmedchem.6b00695","article-title":"Exploring the N-terminal region of C-X-C motif chemokine 12 (CXCL12): identification of plasma-stable cyclic peptides as novel, potent C-X-C chemokine receptor type 4 (CXCR4) antagonists","volume":"59","author":"Di Maro","year":"2016","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9641","DOI":"10.1021\/acs.jmedchem.7b01062","article-title":"Structure\u2013activity relationships and biological characterization of a novel, potent, and serum stable C-X-C chemokine receptor type 4 (CXCR4) antagonist","volume":"60","author":"Di Maro","year":"2017","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.2967\/jnumed.125.270807","article-title":"CXCR4 PET\/CT predicts left ventricular recovery 8 months after acute myocardial infarction","volume":"66","author":"Diekmann","year":"2025","journal-title":"J. Nucl. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.V110.11.445.445","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation","volume":"110","author":"DiPersio","year":"2007","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nm0198-072","article-title":"AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor","volume":"4","author":"Donzella","year":"1998","journal-title":"Nat. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.2967\/jnumed.124.268169","article-title":"C-X-C Motif chemokine receptor 4\u2013Directed scintigraphy using [99mTc]Tc-Pentixatec in primary aldosteronism: a proof-of-concept study","volume":"65","author":"Enke","year":"2024","journal-title":"J. Nucl. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"112410","DOI":"10.1016\/j.ejmech.2020.112410","article-title":"Design, synthesis, and biological characterization of a new class of symmetrical polyamine-based small molecule CXCR4 antagonists","volume":"200","author":"Fang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13287-020-02073-z","article-title":"A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys","volume":"12","author":"Fang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"114150","DOI":"10.1016\/j.ejmech.2022.114150","article-title":"A fragment integrational approach to GPCR inhibition: identification of a high affinity small molecule CXCR4 antagonist","volume":"231","author":"Fang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"02168","DOI":"10.3389\/fimmu.2020.02168","article-title":"CXCR4 inhibition counteracts immunosuppressive properties of metastatic NSCLC stem cells","volume":"11","author":"Fortunato","year":"2020","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1002\/anie.200351024","article-title":"Molecular-size reduction of a potent CXCR4-Chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries","volume":"42","author":"Fujii","year":"2003","journal-title":"Angew. Chem. Int. Ed."},{"key":"B35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00330-022-09058-x","article-title":"Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET\/CT","volume":"33","author":"Gao","year":"2023","journal-title":"Eur. Radiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"14153","DOI":"10.1074\/jbc.M010429200","article-title":"Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor","volume":"276","author":"Gerlach","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/bi0264770","article-title":"Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor","volume":"42","author":"Gerlach","year":"2003","journal-title":"Biochemistry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a 68Ga-Labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J. Nucl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nucmedbio.2006.01.006","article-title":"Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors","volume":"33","author":"Hanaoka","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2967\/jnumed.121.262295","article-title":"Biokinetics and dosimetry of [177Lu]Lu-Pentixather","volume":"63","author":"H\u00e4nscheid","year":"2021","journal-title":"J. Nucl. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0026-895X(24)23060-1","article-title":"Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency Virus-1 entry and abrogates the antagonistic activity of AMD3100","volume":"60","author":"Hatse","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.bcp.2005.05.035","article-title":"AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor","volume":"70","author":"Hatse","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1128\/aac.44.6.1667-1673.2000","article-title":"Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers","volume":"44","author":"Hendrix","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2967\/jnumed.116.179663","article-title":"Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-Pentixafor for PET","volume":"58","author":"Hyafil","year":"2017","journal-title":"J. Nucl. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.bmc.2009.01.014","article-title":"64Cu-AMD3100\u2014A novel imaging agent for targeting chemokine receptor CXCR4","volume":"17","author":"Jacobson","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12931-020-01467-0","article-title":"CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis","volume":"21","author":"Jaffar","year":"2020","journal-title":"Respir. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/cmi.2017.107","article-title":"The unique structural and functional features of CXCL12","volume":"15","author":"Janssens","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e71283","DOI":"10.1096\/fj.202501658RR","article-title":"Spatial myeloid landscape of large artery atherosclerotic and cardioembolic thrombi retrieved by mechanical thrombectomy","volume":"39","author":"Jo","year":"2025","journal-title":"FASEB J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1172\/JCI71606","article-title":"Mechanisms of lymphatic metastasis","volume":"124","author":"Karaman","year":"2014","journal-title":"J. Clin. Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"10411","DOI":"10.1158\/0008-5472.CAN-10-2591","article-title":"CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche","volume":"70","author":"Kim","year":"2010","journal-title":"Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2967\/jnumed.119.234484","article-title":"Imaging inflammation in atherosclerosis with CXCR4-directed 68Ga-pentixafor PET\/CT: correlation with 18F-FDG PET\/CT","volume":"61","author":"Kircher","year":"2020","journal-title":"J. Nucl. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1007\/s00259-023-06395-x","article-title":"[99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience","volume":"50","author":"Konrad","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B55","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1021\/acs.chemrev.8b00294","article-title":"Radioactive main group and rare Earth metals for imaging and therapy","volume":"119","author":"Kostelnik","year":"2019","journal-title":"Chem. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3109\/03602530903491824","article-title":"Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters","volume":"42","author":"Kusuhara","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"B57","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/978-3-032-21415-7_17","article-title":"Clinical applications of theranostics","volume-title":"Molecular Imaging in Oncology - Volume 2: Advanced Solutions to Acquire Disease-specific Biomarkers - Clinical Applications","author":"Kuten","year":"2026"},{"key":"B58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1021\/acs.molpharmaceut.0c00785","article-title":"High-contrast CXCR4-Targeted 18F-PET imaging using a potent and selective antagonist","volume":"18","author":"Kwon","year":"2021","journal-title":"Mol. Pharm."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-21-3284","article-title":"Targeting refractory mantle cell lymphoma for imaging and therapy using C-X-C chemokine receptor type 4 radioligands","volume":"28","author":"Kwon","year":"","journal-title":"Clin. Cancer Res."},{"key":"B60","first-page":"2579","article-title":"[18F]Trifluoroborate-based CXCR4-targeting PET agents based on a potent and novel pharmacophore. [Abstract]","volume":"63","author":"Kwon","year":"","journal-title":"J. Nucl. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/pharmaceutics14071502","article-title":"Reducing the kidney uptake of high contrast CXCR4 PET imaging agents via linker modifications","volume":"14","author":"Kwon","year":"","journal-title":"Pharmaceutics"},{"key":"B62","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2967\/jnumed.125.269933","article-title":"Development of an optimized CXCR4-targeting theranostic pair","volume":"67","author":"Kwon","year":"2026","journal-title":"J. Nucl. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","author":"Lapa","year":"","journal-title":"Theranostics"},{"key":"B64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"","journal-title":"Theranostics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2967\/jnumed.118.210997","article-title":"Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma","volume":"60","author":"Lapa","year":"2019","journal-title":"J. Nucl. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1021\/acs.molpharmaceut.9b00808","article-title":"[68Ga]Ga\/[177Lu]Lu-BL01, a novel theranostic pair for targeting C-X-C chemokine receptor 4","volume":"16","author":"Lau","year":"2019","journal-title":"Mol. Pharm."},{"key":"B67","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/acsomega.6b00086","article-title":"Predicting binding affinities for GPCR ligands using free-energy perturbation","volume":"1","author":"Lenselink","year":"2016","journal-title":"ACS Omega"},{"key":"B68","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/acs.bioconjchem.4c00167","article-title":"18F-Radiolabeling and evaluation of an AMD3465 derivative for PET imaging of CXCR4 in a mouse breast tumor model","volume":"35","author":"Li","year":"2024","journal-title":"Bioconjugate Chem."},{"key":"B127","first-page":"e016992","article-title":"[99mTc]-PentixaTec SPECT\/CT for imaging of chemokine receptor 4 expression after myocardial infarction","volume-title":"Circulation: Cardiovascular Imaging","author":"Liebich","year":"2024"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.jacc.2011.08.033","article-title":"Double-edged role of the CXCL12\/CXCR4 axis in experimental myocardial infarction","volume":"58","author":"Liehn","year":"2011","journal-title":"JACC"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","article-title":"Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist","volume":"102","author":"Liles","year":"2003","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"114578","DOI":"10.1016\/j.celrep.2024.114578","article-title":"Cryo-EM structure of monomeric CXCL12-bound CXCR4 in the active state","volume":"43","author":"Liu","year":"2024","journal-title":"Cell Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"115255","DOI":"10.1016\/j.celrep.2025.115255","article-title":"Structural basis of CXCR4 assembly and regulation","volume":"44","author":"Liu","year":"2025","journal-title":"Cell Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1021\/bi9812726","article-title":"Dynamics study on the anti-human immunodeficiency virus chemokine viral macrophage-inflammatory Protein-II (VMIP-II) reveals a fully monomeric protein","volume":"38","author":"LiWang","year":"1999","journal-title":"Biochemistry"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","article-title":"68Ga-Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET\/CT","volume":"60","author":"Luo","year":"2019","journal-title":"J. Nucl. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/pharmaceutics13101619","article-title":"D-peptide-based probe for CXCR4-targeted molecular imaging and radionuclide therapy","volume":"13","author":"Luyten","year":"2021","journal-title":"Pharmaceutics"},{"key":"B76","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/JLB.5BT1219-714R","article-title":"At the bedside: profiling and treating patients with CXCR4-expressing cancers","volume":"109","author":"Martin","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","article-title":"Side effects of CXC-chemokine receptor 4\u2013directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation","volume":"60","author":"Maurer","year":"2019","journal-title":"J. Nucl. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET","volume":"11","author":"Mayerhoefer","year":"2021","journal-title":"Theranostics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/bc200608e","article-title":"New lyophilized kit for rapid radiofluorination of peptides","volume":"23","author":"McBride","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1021\/acs.bioconjchem.6b00561","article-title":"Click chemistry and radiochemistry: the first 10 years","volume":"27","author":"Meyer","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s44386-025-00019-0","article-title":"AI meets physics in computational structure-based drug discovery for GPCRs","volume":"2","author":"Michino","year":"2025","journal-title":"Npj Drug Discov."},{"key":"B82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jneuroim.2008.04.008","article-title":"CXCR4 signaling in the regulation of stem cell migration and development","volume":"198","author":"Miller","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"30155","DOI":"10.1038\/srep30155","article-title":"Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists","volume":"6","author":"Mishra","year":"2016","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and chemokine receptors: new targets for cancer immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15384047.2019.1665405","article-title":"CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of waldenstr\u00f6m macroglobulinemia","volume":"21","author":"Muz","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1021\/acs.jmedchem.8b00450","article-title":"Design, synthesis, and pharmacological evaluation of second-generation tetrahydroisoquinoline-based CXCR4 antagonists with favorable ADME properties","volume":"61","author":"Nguyen","year":"2018","journal-title":"J. Med. Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1158\/0008-5472.CAN-09-4396","article-title":"Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography","volume":"70","author":"Nimmagadda","year":"2010","journal-title":"Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"8264","DOI":"10.7150\/thno.45537","article-title":"A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency","volume":"10","author":"Osl","year":"2020","journal-title":"Theranostics"},{"key":"B89","doi-asserted-by":"publisher","first-page":"115240","DOI":"10.1016\/j.bmc.2019.115240","article-title":"A benzenesulfonamide derivative as a novel PET radioligand for CXCR4","volume":"28","author":"Oum","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.MCT-14-0850","article-title":"Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models","volume":"14","author":"Peng","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1021\/acs.molpharmaceut.1c00600","article-title":"Preclinical evaluation of [64Cu]NOTA-CP01 as a PET imaging agent for metastatic esophageal squamous cell carcinoma","volume":"18","author":"Peng","year":"2021","journal-title":"Mol. Pharm."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e74548","DOI":"10.1371\/journal.pone.0074548","article-title":"Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases","volume":"8","author":"Portella","year":"2013","journal-title":"PLOS ONE"},{"key":"B93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-016-0193-8","article-title":"The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity","volume":"6","author":"Poschenrieder","year":"2016","journal-title":"EJNMMI Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41181-016-0020-6","article-title":"[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model","volume":"2","author":"Poschenrieder","year":"2017","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1021\/acs.bioconjchem.5b00689","article-title":"AMD3100: a versatile platform for CXCR4 Targeting68 Ga-based radiopharmaceuticals","volume":"27","author":"Poty","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1126\/science.1261064","article-title":"Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine","volume":"347","author":"Qin","year":"2015","journal-title":"Science"},{"key":"B97","doi-asserted-by":"publisher","first-page":"108335","DOI":"10.1016\/j.nucmedbio.2023.108335","article-title":"In vivo validation of 68Ga-labeled AMD3100 conjugates for PET imaging of CXCR4","author":"Renard","year":"2023","journal-title":"Nucl. Med. Biol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1073\/pnas.2235846100","article-title":"A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors","volume":"100","author":"Rubin","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e2425795122","DOI":"10.1073\/pnas.2425795122","article-title":"Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists","volume":"122","author":"Sang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B100","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41594-024-01397-1","article-title":"Structural insights into CXCR4 modulation and oligomerization","volume":"32","author":"Saotome","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.7150\/thno.19119","article-title":"[177Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent","volume":"7","author":"Schottelius","year":"2017","journal-title":"Theranostics"},{"key":"B102","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13550-019-0545-2","article-title":"Validation of [125I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo","volume":"9","author":"Schottelius","year":"2019","journal-title":"EJNMMI Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1021\/jm100073m","article-title":"Discovery of novel small molecule orally bioavailable C\u2212X\u2212C chemokine receptor 4 antagonists that are potent inhibitors of T-Tropic (X4) HIV-1 replication","volume":"53","author":"Skerlj","year":"2010","journal-title":"J. Med. Chem."},{"key":"B105","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","article-title":"CXCR4 regulates growth of both primary and metastatic breast cancer","volume":"64","author":"Smith","year":"2004","journal-title":"Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"108906","DOI":"10.1016\/j.nucmedbio.2024.108906","article-title":"Second generation Al18F-labeled D-amino acid peptide for CXCR4 targeted molecular imaging","author":"Spahn","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00259-024-07025-w","article-title":"Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924","volume":"52","author":"Spahn","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B108","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s41181-024-00290-y","article-title":"Radiosynthesis and preclinical evaluation of a 68Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma","volume":"9","author":"Suwattananuruk","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"15284","DOI":"10.1038\/s41598-019-51754-0","article-title":"C-terminal\u2013modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4","volume":"9","author":"Suzuki","year":"2019","journal-title":"Sci. Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/PMC.S422","article-title":"Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing","volume":"2","author":"Tamamura","year":"2008","journal-title":"Perspect. Med. Chem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"12667","DOI":"10.1128\/jvi.79.20.12667-12673.2005","article-title":"Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1\u03b1 on CXCR4 transmembrane helical domains","volume":"79","author":"Tian","year":"2005","journal-title":"J. Virol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1021\/acs.jmedchem.1c00066","article-title":"Novel peptide-based PET probe for non-invasive imaging of C-X-C chemokine receptor type 4 (CXCR4) in tumors","volume":"64","author":"Trotta","year":"2021","journal-title":"J. Med. Chem."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1021\/ml400183q","article-title":"Discovery of tetrahydroisoquinoline-based CXCR4 antagonists","volume":"4","author":"Truax","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"B114","doi-asserted-by":"publisher","first-page":"17221","DOI":"10.1021\/acs.jmedchem.5c00735","article-title":"Synthesis and evaluation of novel C-X-C chemokine receptor 4-Targeted radiotracers for oncological imaging","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-26-0292","article-title":"Design, preclinical evaluation, and clinical translation of [68Ga]Ga\/[177Lu]Lu-JH120061, A novel radiopharmaceutical targeting CXCR4","author":"Wang","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11307-010-0466-y","article-title":"Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100","volume":"14","author":"Weiss","year":"2012","journal-title":"Mol. Imaging Biol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 chemokine receptor in complex with small molecule and cyclic peptide antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bbrc.2013.05.038","article-title":"A synthetic bivalent ligand of CXCR4 inhibits HIV infection","volume":"435","author":"Xu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B120","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.7150\/thno.130266","article-title":"The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015\u20132025)","volume":"16","author":"Yang","year":"2026","journal-title":"Theranostics"},{"key":"B121","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.3390\/molecules28124707","article-title":"CXCR4-Targeted radiopharmaceuticals for the imaging and therapy of malignant tumors","volume":"28","author":"Yu","year":"2023","journal-title":"Molecules"},{"key":"B122","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1021\/acs.jmedchem.5c03763","article-title":"68Ga\/161Tb-Labeled CXCR4-Targeted probe with enhanced positive charge: improved affinity and longer tumor retention without survival benefit in mice models","volume":"69","author":"Yu","year":"2026","journal-title":"J. Med. Chem."},{"key":"B128","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1038\/s41467-025-63815-2","article-title":"CXCR4 mediated recognition of HIV envelope spike and inhibition by CXCL12","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1021\/bi992750v","article-title":"A novel peptide antagonist of CXCR4 derived from the N-Terminus of viral chemokine vMIP-II","volume":"39","author":"Zhou","year":"2000","journal-title":"Biochemistry"},{"key":"B124","doi-asserted-by":"publisher","first-page":"17476","DOI":"10.1074\/jbc.M202063200","article-title":"Exploring the stereochemistry of CXCR4-Peptide recognition and inhibiting HIV-1 entry with d-Peptides derived from chemokines","volume":"277","author":"Zhou","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B125","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1923347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:23:37Z","timestamp":1788528217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1923347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":129,"alternative-id":["10.3389\/fphar.2026.1923347"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1923347","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1923347"}}